Surveillance of emerging SARS-CoV-2 variants by nanopore technology-based genome sequencing

Abstract

Objective: To surveill emerging variants by nanopore technology-based genome sequencing in different COVID-19 waves in Sri Lanka and to examine the association with the sample characteristics, and vaccination status. Methods: The study analyzed 207 RNA positive swab samples received to sequence laboratory during different waves. The N gene cut-off threshold of less than 30 was considered as the major inclusion criteria. Viral RNA was extracted, and elutes were subjected to nanopore sequencing. All the sequencing data were uploaded in the publicly accessible database, GISAID. Results: The Omicron, Delta and Alpha variants accounted for 58%, 22% and 4% of the variants throughout the period. Less than 1% were Kappa variant and 16% of the study samples remained unassigned. Omicron variant was circulated among all age groups and in all the provinces. Ct value and variants assigned percentage was 100% in Ct values of 10-15 while only 45% assigned Ct value over 25. Conclusions: The present study examined the emergence, prevalence, and distribution of SARS-CoV-2 variants locally and has shown that nanopore technology-based genome sequencing enables whole genome sequencing in a low resource setting country.

Keywords

Emerging SARS-CoV-2 variants / Laboratory surveillance / Nanopore technology / Genome sequencing / Bioinformatics analysis and phylogeny / Sociodemographic and sample cutoff (Ct) threshold / Global sharing of genomic data/GISAID

References

[1] Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, et al. Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. Nat Commun 2021; 12(1):5730. doi: 10.1038/s41467-021-25915-7.

[2] World Health Organization. WHO guidance for surveillance of SARS-CoV-2 variants: Interim guidance. [Online]. Available from:https://www.who.int/publications-detail-redirect/WHO_2019-nCoV_surveillance_variants. [Accessed on 1 February 2023].

[3] Yavarian J, Nejati A, Salimi V, Shafiei Jandaghi NZ, Sadeghi K, Abedi A, et al. Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. PLoS One 2022; 17(5):e0267847. doi: 10.1371/journal.pone.0267847.

[4] Cheng XW, Li J, Zhang L, Hu WJ, Zong L, Xu X, et al. Identification of SARS-CoV-2 variants and their clinical significance in Hefei, China. Front Med 2022; 8:784632. doi: 10.3389/fmed.2021.784632

[5] Anna Y, Ganna K, Matthew R, Mariia GL, Eric B, Viktoria IZ. Tracking SARS-COV-2 variants using nanopore sequencing in Ukraine in 2021. Sci Rep 2022; 12:15749.

[6] Wikipedia. Whole genome sequencing. [Online]. Available from:https://en.wikipedia.org/wiki/Whole_genome_sequencing.[Accessed on 8 December2022].

[7] Tshiabuila D, Giandhari J, Pillay S, Ramphal U, Ramphal Y, Maharaj A, et al. Comparison of SARS-CoV-2 sequencing using the ONT GridION and the Illumina MiSeq. BMC Genom 2022; 23(1):319. doi: 10.1186/s12864-022-08541-5.

[8] Okoniewski M, Płoski R, Wiewiorka M, Demkow U. Future directions. In: Clinical applications for next-generation sequencing. Urszula Demkow, Rafał Płoski. (eds.). Cambridge: Academic Press; 2016, p. 281-294.

[9] Ministry of Health, Sri Lanka. Request form and the instructions to send the sample for SARS-CoV-2 gene sequencing testing, General Circular Letter No: 01-47/2021. [Online]. Available from:https://www.epid.gov.lk/web/images/pdf/Circulars/Corona_virus/request_form_and_the_instructions_to_send.pdf . [Accessed on 1 January 2023].

[10] Juanola-Falgarona M, Peñarrubia L, Jiménez-Guzmán S, Porco R, Congost-Teixidor C, Varo-Velázquez M, et al. Ct values as a diagnostic tool for monitoring SARS-CoV-2 viral load using the QIAstat-Dx® Respiratory SARS-CoV-2 Panel. Int J Infect Dis 2022; 122:930-935.

[11] QIAGEN group. QIAamp viral RNA mini kit 250. [Online]. Available from:https://www.qiagen.com/virus. [Accessed on 3 February 2023].

[12] Freed NE, Vlková M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1 200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biol Methods Protoc 2020; 5(1):bpaa014. doi: 10.1093/biomethods/bpaa014.

[13] Centers for Disease Control and Prevention (CDC). CDC’s role in tracking emerging COVID-19 variants. [Online]. Available from:https://www.cdc.gov/coronavirus/2019-ncov/variants/ cdc-role-surveillance.html. [Accessed on 16 January 2023].

[14] Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19(7):409-424. doi: 10.1038/s41579-021-00573-0.

[15] Ou J, Zhou Z, Dai R, Zhang J, Zhao S, Wu X, et al. V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. J Virol 2021; 95(16):e0061721. doi: 10.1128/JVI.00617-21.

[16] Goswami C, Sheldon M, Bixby C, Keddache M, Bogdanowicz A, Wang Y, et al. Identification of SARS-CoV-2 variants using viral sequencing for the Centers for Disease Control and Prevention genomic surveillance program. BMC Infect Dis 2022; 22(1):404. doi: 10.1186/s12879-022-07374-7.

[17] Shen L, Dien Bard J, Biegel JA, Judkins AR, Gai X. Comprehensive genome analysis of 6 000 USA SARS-CoV-2 isolates reveals haplotype signatures and localized transmission patterns by State and by Country. Front Microbiol 2020; 11:573430. doi: 10.3389/fmicb.2020.573430.

[18] Page AJ, Mather AE, Le-Viet T, Meader EJ, Alikhan NF, Kay GL, et al. The covid-genomics Uk Cog-Uk consortium. Large-scale sequencing of SARS-CoV-2 genomes from one region allows detailed epidemiology and enables local outbreak management. Microb Genom 2021; 7(6):000589. doi: 10.1099/mgen.0.000589.

[19] Dächert C, Muenchhoff M, Graf A, Autenrieth H, Bender S, Mairhofer H, et al. Rapid and sensitive identification of omicron by variant-specific PCR and nanopore sequencing: Paradigm for diagnostics of emerging SARS-CoV-2 variants. Med Microbiol Immunol 2022; 211(1):71-77. doi: 10.1007/s00430-022-00728-7.

[20] Bull RA, Adikari TN, Ferguson JM, Hammond JM, Stevanovski I, Beukers AG, et al. Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. Nat Commun 2020; 11(1):6272. doi: 10.1038/s41467-020-20075-6.

[21] Lanfear R, Schalamun M, Kainer D, Wang W, Schwessinger B. MinIONQC: Fast and simple quality control for MinION sequencing data. Bioinformatics 2019; 35(3):523-525. doi: 10.1093/bioinformatics/bty654.

[22] Cheng VCC, Ip JD, Chu AWH, Tam AR, Chan WM, Abdullah SMU, et al. Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 in a single-source community outbreak. Clin Infect Dis 2022; 75(1):e44-e49. doi: 10.1093/cid/ciac203.

[23] U.S. Food & Drug Administration. SARS-CoV-2 viral mutations: Impact on COVID-19 tests. FDA, 12th January 2023. [Online]. Available from:https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests?wpisrc=nl_tyh. [Accessed on 30 January 2023].

[24] World Health Organization. TAG-VE statement on Omicron sub lineages BQ.1 and XBB. 27th October 2022. [Online]. Available from:https://www.who.int/news/item/27-10-2022-tag-ve-statement-on-omicron-sublineages-bq.1-and-xbb. [Accessed on 30 January 2023].

[25] Smith-Schoenwalder C. CDC: Omicron Subvariants BA.4.6, BF.7 increasing while BA.5 declines. [Online]. Available from:https://www.usnews.com/news/health-news/articles/2022-10-07/cdc-omicron-subvariants-ba-4-6-bf-7-increasing-while-ba-5-declines. [Accessed on 30 January 2023].